Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527

Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine

Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · doi:10.1101/2021.07.28.21261159 · Cited by 1,640

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110345 · Cited by 1,640

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389

The Development of a Standardized Neighborhood Deprivation Index

Messer, L. C., Laraia, B. A., Kaufman, J. S., Eyster, J. T., Holzman, C., Culhane, J. F., Elo, I. T., Burke, J. G., & O'Campo, P. J. (2006) · Journal of Urban Health · doi:10.1007/s11524-006-9094-x · Cited by 1,046

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.

Sheikh, A., McMenamin, J., Taylor, B., & Robertson, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01358-1 · Cited by 939

Length of hospital stay and risk of intensive care admission and in-hospital death among COVID-19 patients in Norway: a register-based cohort study comparing patients fully vaccinated with an mRNA vaccine to unvaccinated patients

Whittaker, R. N., Kristoffersen, A. B., Salamanca, B. V., Seppälä, E. M., Golestani, K., Kvåle, R., Watle, S. V., & Buanes, E. A. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.01.033 · Cited by 67

Protection by Vaccines and Previous Infection Against the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2

Šmíd, M., Berec, L., Přibylová, L., Májek, O., Pavlík, T., Jarkovský, J., Weiner, J., Barusová, T., & Trnka, J. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac161 · Cited by 67

Fear of COVID-19 predicts vaccination willingness 14 months later

Mertens, G., Lodder, P., Smeets, T., & Duijndam, S. (2022) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2022.102574 · Cited by 66

Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study

Sritipsukho, P., Khawcharoenporn, T., Siribumrungwong, B., Damronglerd, P., Suwantarat, N., Satdhabudha, A., Chaiyakulsil, C., Sinlapamongkolkul, P., Tangsathapornpong, A., Bunjoungmanee, P., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2037398 · Cited by 65

Defending against SARS-CoV-2: The T cell perspective

Almendro-Vázquez, P., Laguna‐Goya, R., & Paz‐Artal, E. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1107803 · Cited by 67

Waning of SARS-CoV-2 booster viral-load reduction effectiveness

Levine-Tiefenbrun, M., Yelin, I., Alapi, H., Herzel, E., Kuint, J., Chodick, G., Gazit, S., Patalon, T., & Kishony, R. (2022) · Nature Communications · doi:10.1038/s41467-022-28936-y · Cited by 63

Effectiveness of COVID-19 Vaccines against Delta (B.1.617.2) Variant: A Systematic Review and Meta-Analysis of Clinical Studies

Pormohammad, A., Zarei, M., Ghorbani, S., Mohammadi, M., Neshin, S. A. S., Khatami, A., Turner, D., Djalalinia, S., Mousavi, S. A., Mardani-Fard, H. A., et al. (2021) · Vaccines · doi:10.3390/vaccines10010023 · Cited by 60

Multiple COVID-19 Waves and Vaccination Effectiveness in the United States

Lin, L., Zhao, Y., Chen, B., & He, D. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19042282 · Cited by 62

Waning effectiveness of COVID-19 vaccines

Chemaitelly, H. S., & Abu-Raddad, L. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00277-x · Cited by 62

Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination

Assawakosri, S., Kanokudom, S., Suntronwong, N., Auphimai, C., Nilyanimit, P., Vichaiwattana, P., Thongmee, T., Duangchinda, T., Chantima, W., Pakchotanon, P., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac092 · Cited by 60

Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records

Horne, E. M. F., Hulme, W. J., Keogh, R. H., Palmer, T., Williamson, E., Parker, E. P. K., Green, A. C. A., Walker, V. M., Walker, A. J., Curtis, H. J., et al. (2022) · BMJ · doi:10.1136/bmj-2022-071249 · Cited by 54

Vaccine versus Variants (3Vs): Are the COVID-19 Vaccines Effective against the Variants? A Systematic Review

Hayawi, K., Shahriar, S., Serhani, M. A., Alashwal, H., & Masud, M. M. (2021) · Vaccines · doi:10.3390/vaccines9111305 · Cited by 58

Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines

Mouro, V., & Fischer, A. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00517-8 · Cited by 56

Development of functionally relevant potency assays for monovalent and multivalent vaccines delivered by evolving technologies

Sanyal, G. (2022) · npj Vaccines · doi:10.1038/s41541-022-00470-4 · Cited by 58

Modeling COVID-19 dynamic using a two-strain model with vaccination

de León, U. A.-P., Avila-Vales, E. J., & Huang, K. (2022) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2022.111927 · Cited by 59

Trained Immunity: An Overview and the Impact on COVID-19

Brueggeman, J., Zhao, J., Schank, M., Yao, Z. Q., & Moorman, J. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.837524 · Cited by 58

Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults

Yorsaeng, R., Suntronwong, N., Phowatthanasathian, H., Assawakosri, S., Kanokudom, S., Thongmee, T., Vichaiwattana, P., Auphimai, C., Wongsrisang, L., Srimuan, D., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.11.083 · Cited by 57

Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: the Danish Nationwide ENFORCE Study

Søgaard, O. S., Reekie, J., Johansen, I. S., Nielsen, H., Benfield, T., Wiese, L., Stærke, N. B., Iversen, K. K., Fogh, K., Bodilsen, J., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.03.003 · Cited by 59

Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose

Rénia, L., Goh, Y. S., Rouers, A., Bert, N. L., Chia, W. N., Chavatte, J., Fong, S., Chang, Z. W., Zhuo, N. Z., Tay, M. Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32312-1 · Cited by 62

Role of T cells in severe COVID-19 disease, protection, and long term immunity

Hermens, J. M., & Keşmir, C. (2023) · Immunogenetics · doi:10.1007/s00251-023-01294-9 · Cited by 57

HLA-A∗03:01 is associated with increased risk of fever, chills, and stronger side effects from Pfizer-BioNTech COVID-19 vaccination

Bolze, A., Neveux, I., Barrett, K. M. S., White, S. J., Isaksson, M., Dabe, S., Lee, W., Grzymski, J. J., Washington, N. L., & Cirulli, E. T. (2022) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2021.100084 · Cited by 55

Duration of immunity following full vaccination against SARS-CoV-2: a systematic review

Addo, I. Y., Dadzie, F. A., Okeke, S. R., Boadi, C., & Boadu, E. F. (2022) · Archives of Public Health · doi:10.1186/s13690-022-00935-x · Cited by 58

Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications

Abebe, E. C., & Dejenie, T. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1055457 · Cited by 58

Longitudinal Study of DNA Methylation and Epigenetic Clocks Prior to and Following Test-Confirmed COVID-19 and mRNA Vaccination

Pang, A. P. S., Higgins‐Chen, A., Comite, F., Raica, I., Arboleda, C., Went, H., Mendez, T. L., Schotsaert, M., Dwaraka, V. B., Smith, R. C., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.819749 · Cited by 53

An extended interval between vaccination and infection enhances hybrid immunity against SARS-CoV-2 variants

Bates, T. A., Leier, H. C., McBride, S. K., Schoen, D., Lyski, Z. L., Lee, D. X., Messer, W. B., Curlin, M. E., & Tafesse, F. (2023) · JCI Insight · doi:10.1172/jci.insight.165265 · Cited by 57

Will the COVID-19 pandemic end with the Delta and Omicron variants?

Wang, C., & Han, J. (2022) · Environmental Chemistry Letters · doi:10.1007/s10311-021-01369-7 · Cited by 52

SARS-CoV-2: phenotype, genotype, and characterization of different variants

Saberiyan, M., Karimi, E., Khademi, Z., Movahhed, P., Safi, A., & Ghahfarrokhi, A. M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00352-6 · Cited by 56

Association Between Vaccination Status and Mortality Among Intubated Patients With COVID-19–Related Acute Respiratory Distress Syndrome

Grapsa, E. J., Adamos, G., Andrianopoulos, I., Tsolaki, V., Giannakoulis, V. G., Karavidas, N., Giannopoulou, V., Sarri, K. O., Mizi, E., Gavrielatou, E., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.35219 · Cited by 54

Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era

Wang, S. Y., Juthani, P. V., Borges, K. A., Shallow, M., Gupta, A. K., Price, C. C., Won, C. H. J., & Chun, H. J. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00306-2 · Cited by 48

Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic

Solante, R., Álvarez, C., Burhan, E., Chariyalertsak, S., Chiu, N., Chuenkitmongkol, S., Dung, D. V., Hwang, K., Ibarra, J. O., Kiertiburanakul, S., et al. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2143347 · Cited by 51

Vaccine Effectiveness Against SARS-CoV-2 Infection and Severe Outcomes in the Maintenance Dialysis Population in Ontario, Canada

Oliver, M. J., Thomas, D., Balamchi, S., Ip, J., Naylor, K., Dixon, S. N., McArthur, E., Kwong, J. C., Perl, J., Atiquzzaman, M., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021091262 · Cited by 49

Population-level implications of the Israeli booster campaign to curtail COVID-19 resurgence

Gavish, N., Yaari, R., Huppert, A., & Katriel, G. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn9836 · Cited by 49

Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens

Moore, S. C., Kronsteiner, B., Longet, S., Adele, S., Deeks, A. S., Liu, C., Dejnirattisai, W., Silva-Reyes, L., Meardon, N., Faustini, S. E., et al. (2023) · Med · doi:10.1016/j.medj.2023.02.004 · Cited by 56

Trends and Risk Factors of In-Hospital Mortality of Patients with COVID-19 in Germany: Results of a Large Nationwide Inpatient Sample

Hobohm, L., Sagoschen, I., Barco, S., Schmidtmann, I. M., Espinola–Klein, C., Konstantinides, S., Münzel, T. F., & Keller, K. (2022) · Viruses · doi:10.3390/v14020275 · Cited by 54

Potential implications of lipid nanoparticles in the pathogenesis of myocarditis associated with the use of mRNA vaccines against SARS-CoV-2

Tsilingiris, D., Vallianou, N. G., Karampela, Ι., Liu, J., & Dalamaga, Μ. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100159 · Cited by 51

Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study

Yamamoto, S., Maeda, K., Matsuda, K., Tanaka, A., Horii, K., Okudera, K., Takeuchi, J. S., Mizoue, T., Konishi, M., Ozeki, M., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1048 · Cited by 47

Knowledge, attitudes, and practices of pregnant women regarding COVID‐19 vaccination in pregnancy in 7 low‐ and middle‐income countries: An observational trial from the Global Network for Women and Children’s Health Research

Naqvi, S., Saleem, S., Naqvi, F., Billah, S. M., Nielsen, E., Fogleman, E., Peres‐da‐Silva, N., Figueroa, L., Mazariegos, M., Garces, A. L., et al. (2022) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.17226 · Cited by 49

The effectiveness of COVID-19 vaccines against severe cases and deaths in Brazil from 2021 to 2022: a registry-based study

dos Santos, C. V. B., Valiati, N. C. M., de Noronha, T. G., Pôrto, V. B. G., Pacheco, A. G., Freitas, L. P., Coelho, F. C., Gomes, M. F. D. C., Bastos, L. S., Cruz, O. G., et al. (2023) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2023.100465 · Cited by 52

Advances in the design and delivery of RNA vaccines for infectious diseases

Lokras, A. G., Bobak, T. R., Baghel, S. S., Sebastiani, F., & Foged, C. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115419 · Cited by 52

Understanding the dynamic relation between wastewater SARS-CoV-2 signal and clinical metrics throughout the pandemic

Hegazy, N., Cowan, A., D’Aoust, P. M., Mercier, É., Towhid, S. T., Jia, J., Wan, S., Zhang, Z., Kabir, M. P., Fang, W., et al. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.158458 · Cited by 43

Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review

Nanishi, E., Levy, O., & Ozonoff, A. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2045857 · Cited by 46

Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial

Jin, P., Guo, X., Chen, W., Ma, S.-H., Pan, H., Dai, L., Du, P., Wang, L., Jin, L., Chen, Y., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1003953 · Cited by 46

Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines During the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study)

(2022) · doi:10.3389/fimmu.2022.905585 · Cited by 46

Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia

Berec, L., Šmíd, M., Přibylová, L., Májek, O., Pavlík, T., Jarkovský, J., Zajíček, M., Weiner, J., Barusová, T., & Trnka, J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0270801 · Cited by 45

High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron

Baum, U., Poukka, E., Leino, T. M., Kilpi, T. M., Nohynek, H., & PALMU, A. A. I. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07814-4 · Cited by 47

Effectiveness of first, second, and third COVID-19 vaccine doses in solid organ transplant recipients: A population-based cohort study from Canada

Naylor, K. L., Kim, S. J., Smith, G. H. R., McArthur, E., Kwong, J. C., Dixon, S. N., Treleaven, D. J., & Knoll, G. A. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17095 · Cited by 47

Intranasal administration of a recombinant RBD vaccine induces long-term immunity against Omicron-included SARS-CoV-2 variants

Hong, L., Alu, A., Yang, J., Ren, W., He, C., Lan, T., He, X., Yang, L., Li, J., Wang, Z., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01002-1 · Cited by 43

Bounding the levels of transmissibility & immune evasion of the Omicron variant in South Africa

Pearson, C. A. B., Silal, S. P., Li, M. W. Z., Dushoff, J., Bolker, B. M., Abbott, S., van Schalkwyk, C., Davies, N. G., Barnard, R. C., Edmunds, W. J., et al. (2021) · doi:10.1101/2021.12.19.21268038 · Cited by 44

COVID ‐19 and plasma cells: Is there long‐lived protection?*

Nguyen, D. C., Lamothe, P. A., Woodruff, M. C., Saini, A. S., Faliti, C. E., Sanz, I., & Lee, F. E.-H. (2022) · Immunological Reviews · doi:10.1111/imr.13115 · Cited by 48

Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study)

Vokó, Z., Kiss, Z., Surján, G., Surján, O., Barcza, Z., Wittmann, I., Molnár, G. A., Nagy, D., Müller, V., Bogos, K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.919408 · Cited by 47

Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study

McKeigue, P., McAllister, D., Hutchinson, S. J., Robertson, C., Stockton, D., & Colhoun, H. M. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00045-5 · Cited by 43

Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2

Salleh, M. Z., Norazmi, M. N., & Deris, Z. Z. (2022) · PeerJ · doi:10.7717/peerj.13083 · Cited by 45

SARS-CoV-2 Vaccine Effectiveness and Breakthrough Infections Among Patients Receiving Maintenance Dialysis

Manley, H. J., Li, N. C., Aweh, G. N., Hsu, C. M., Weiner, D. E., Miskulin, D. C., Harford, A., Johnson, D. S., & Lacson, E. K., Jr. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2022.10.010 · Cited by 44

Cultural and social attitudes towards COVID-19 vaccination and factors associated with vaccine acceptance in adults across the globe: A systematic review

Begum, T., Efstathiou, N., Bailey, C., & Guo, P. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.05.041 · Cited by 49

Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July–November 2021

(2022) · doi:10.1186/s12916-022-02480-4 · Cited by 43

GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults

Palmer, C. D., Scallan, C. D., Kraemer Tardif, L. D., Kachura, M. A., Rappaport, A. R., Koralek, D. O., Uriel, A., Gitlin, L., Klein, J., Davis, M. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39053-9 · Cited by 42

Vaccine-induced protection against SARS-CoV-2 requires IFN-γ-driven cellular immune response

Wang, X., Yuen, T. T., Dou, Y., Hu, J., Li, R., Zeng, Z., Lin, X., Gong, H., Chan, C. H.-C., Yoon, C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39096-y · Cited by 42

COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective

Marcelin, J. R., Pettifor, A. E., Janes, H., Brown, E. R., Kublin, J. G., & Stephenson, K. E. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac124 · Cited by 41

Predicting Vaccine Effectiveness for Hospitalization and Symptomatic Disease for Novel SARS-CoV-2 Variants Using Neutralizing Antibody Titers

Gardner, B. J., & Kilpatrick, A. M. (2024) · Viruses · doi:10.3390/v16030479 · Cited by 43

Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States

Fusco, M. D., Marczell, K., Deger, K. A., Moran, M. M., Wiemken, T. L., Cane, A. D., de Boisvilliers, S., Yang, J., Vaghela, S., & Roïz, J. (2022) · Journal of Medical Economics · doi:10.1080/13696998.2022.2071427 · Cited by 41

Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US

Goswami, H., Alsumali, A., Jiang, Y., Schindler, M., Duke, E. R., Cohen, J., Briggs, A. H., & Puenpatom, A. (2022) · PharmacoEconomics · doi:10.1007/s40273-022-01168-0 · Cited by 41

A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines

He, X., Su, J., Ma, Y., Zhang, W., & Tang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.945930 · Cited by 41

Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge

Bierle, D. M., Ganesh, R., & Razonable, R. R. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.105026 · Cited by 40

Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination

Kato, H., Miyakawa, K., Ohtake, N., Yamaoka, Y., Yajima, S., Yamazaki, E., Shimada, T., Goto, A., Nakajima, H., & Ryo, A. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.057 · Cited by 41

Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate

Hermosilla, J., Alonso-García, A., Salmerón‐García, A., Barrera, J. C., Medina-Castillo, A. L., Pérez-Robles, R., & Navas, N. (2023) · Vaccines · doi:10.3390/vaccines11111635 · Cited by 40

Understanding on the possible routes for SARS CoV-2 invasion via ACE2 in the host linked with multiple organs damage

Kirtipal, N., Kumar, S., Dubey, S. K., Dwivedi, V. D., Babu, K. G., Malý, P., & Bharadwaj, S. (2022) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2022.105254 · Cited by 44

Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variants compared with Alpha variant in vaccinated individuals

Andeweg, S. P., Vennema, H., Veldhuijzen, I. K., Smorenburg, N., Schmitz, D., Zwagemaker, F., van Gageldonk‐Lafeber, A. B., Hahné, S. J. M., Reusken, C. B. E. M., Knol, M. J., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn4338 · Cited by 39

SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes with implications for booster strategies

Mazzoni, A., Vanni, A., Spinicci, M., Lamacchia, G., Kiros, S. T., Rocca, A., Capone, M., Lauria, N. D., Salvati, L., Carnasciali, A., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157990 · Cited by 40

Long-term Real-world Protection Afforded by Third mRNA Doses Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections, Coronavirus Disease 19-related Emergency Attendances and Hospitalizations Amongst Older Singaporeans During an Omicron XBB Wave

Wee, L. E., Pang, D., Chiew, C. J., Tan, J. S. H., Lee, V., Ong, B., Lye, D. C., & Tan, K. B. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad345 · Cited by 38

Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose

Rode, O. Đ., Bodulić, K., Zember, S., Balent, N. C., Novokmet, A., Čulo, M., Rašić, Ž., Mikulić, R., & Markotić, A. (2022) · Vaccines · doi:10.3390/vaccines10020153 · Cited by 41

COVID-19 Vaccination and the Timing of Surgery Following COVID-19 Infection

Le, S., Kipnis, P., Cohn, B. R., & Liu, V. X. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005597 · Cited by 40

Determinants of anti-S immune response at 6 months after COVID-19 vaccination in a multicentric European cohort of healthcare workers – ORCHESTRA project

Collatuzzo, G., Visci, G., Violante, F. S., Porru, S., Spiteri, G., Monaco, M. G. L., Fillon, F. L., Negro, C., Janke, C., Castelletti, N., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.986085 · Cited by 40

Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine

Azzi, L., Gasperina, D. D., Veronesi, G., Shallak, M., Maurino, V., Baj, A., Gianfagna, F., Cavallo, P., Dentali, F., Tettamanti, L., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2022.104435 · Cited by 40

Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers

Schmidt, P., Narayan, K. M., Li, Y., Kaku, C. I., Brown, M. E., Champney, E. R., Geoghegan, J. C., Vásquez, M., Krauland, E. M., Yockachonis, T. J., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg2783 · Cited by 35

Incidence and severity of SARS-CoV-2 infections in liver and kidney transplant recipients in the post-vaccination era: Real-life data from Denmark

Hamm, S. R., Rezahosseini, O., Møller, D. L., Loft, J. A., Poulsen, J. R., Knudsen, J. D., Pedersen, M. S., Schønning, K., Harboe, Z. B., Rasmussen, A., et al. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17141 · Cited by 39

Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses

Almendro-Vázquez, P., Chivite‐Lacaba, M., Utrero‐Rico, A., González‐Cuadrado, C., Laguna‐Goya, R., Moreno-Batanero, M., Sánchez-Paz, L., Luczkowiak, J., Labiod, N., Folgueira, M. D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.981350 · Cited by 37

Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications

Higashikuni, Y., Liu, W., Obana, T., & Sata, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222112081 · Cited by 38

Higher COVID-19 Vaccination Rates Are Associated with Lower COVID-19 Mortality: A Global Analysis

Hoxha, I. S., Agahi, R., Bimbashi, A., Aliu, M., Raka, L., Bajraktari, I., Beqiri, P., & Adams, L. V. (2022) · Vaccines · doi:10.3390/vaccines11010074 · Cited by 37

Protection Duration of COVID-19 Vaccines: Waning Effectiveness and Future Perspective

Zhuang, C., Liu, X., Chen, Q., Yuxin, S., Su, Y., Huang, S., Wu, T., & Xia, N. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.828806 · Cited by 40

Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases

Rouf, N. Z., Biswas, S., Tarannum, N., Oishee, L. M., & Muna, M. M. (2022) · RNA Biology · doi:10.1080/15476286.2022.2055923 · Cited by 39

SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes with implications for booster strategies

Mazzoni, A., Vanni, A., Spinicci, M., Lamacchia, G., Kiros, S. T., Rocca, A., Capone, M., Lauria, N. D., Salvati, L., Carnasciali, A., et al. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 36

Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates

Kaabi, N. A., Oulhaj, A., Ganesan, S., Hosani, F. I. A., Najim, O., Ibrahim, H., Acuna, J. M., Alsuwaidi, A. R., Kamour, A. M., Alzaabi, A. H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30835-1 · Cited by 40

COVID-19 vaccine hesitancy cannot fully explain disparities in vaccination coverage across the contiguous United States

Hu, S., Xiong, C., Li, Q., Wang, Z., & Jiang, Y. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.07.051 · Cited by 34

Vaccine‐induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster

Favresse, J., Gillot, C., Bayart, J., David, C., Simon, G., Wauthier, L., Closset, M., Dogné, J., & Douxfils, J. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28164 · Cited by 33

Effectiveness and durability of BNT162b2 vaccine against hospital and emergency department admissions due to SARS-CoV-2 omicron sub-lineages BA.1 and BA.2 in a large health system in the USA: a test-negative, case-control study

Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V., Frankland, T. B., Xie, F., Ackerson, B. K., Valluri, S. R., Jodar, L., & McLaughlin, J. M. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00354-x · Cited by 36

mRNA vaccines against respiratory viruses

Whitaker, J. A., Sahly, H. M. E., & Healy, C. M. (2023) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000948 · Cited by 39

Macrophages direct location-dependent recall of B cell memory to vaccination

Dhenni, R., Hoppé, A. C., Reynaldi, A., Kyaw, W., Handoko, N. T., Grootveld, A. K., Keith, Y. H., Bhattacharyya, N. D., Ahel, H. I., Telfser, A. J., et al. (2025) · Cell · doi:10.1016/j.cell.2025.04.005 · Cited by 38

Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern

Su, S., Li, W., & Jiang, S. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.01.009 · Cited by 32

Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants

da Silva, S. J. R., de Lima, S. C., da Silva, R. C., Kohl, A., & Pena, L. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.836826 · Cited by 35

Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study

Shrotri, M., Krutikov, M., Nacer, H., Azmi, B., Palmer, T., Giddings, R., Fuller, C., Irwin-Singer, A., Baynton, V., Tut, G., et al. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00147-7 · Cited by 38

Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK

Wei, J., Matthews, P. C., Stoesser, N. E., Newton, J. N., Diamond, I. D., Studley, R., Taylor, N. P., Bell, J. I., Farrar, J., Kolenchery, J. B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38275-1 · Cited by 43

Dynamics of anti-Spike IgG antibody level after the second BNT162b2 COVID-19 vaccination in health care workers

Ikezaki, H., Nakashima, R., Miyoshi, K., Hara, Y., Hayashi, J., Hara, H., Nomura, H., & Shimono, N. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.02.024 · Cited by 35

Global Challenges in Access to and Implementation of Precision Oncology: The Health Care Manager and Health Economist Perspective

Shih, Y. T., Pan, I.-W. E., & Teich, N. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_359650 · Cited by 34

Efficacy and Safety of an Inactivated Whole-Virion Vaccine Against COVID-19, QazCovid-in®, In Healthy Adults: A Multicentre, Randomised, Single-Blind, Placebo-Controlled Phase 3 Clinical Trial With a 6-Month Follow-Up

Khairullin, B. M., Zakarya, K. D., Orynbayev, M. B., Abduraimov, Y. O., Kassenov, M., Sarsenbayeva, G., Sultankulova, K. T., Chervyakova, O. V., Myrzakhmetova, B. S., Куралбаевич, Н. А., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101526 · Cited by 36

Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents

Oliveira, C. R., Niccolai, L. M., Sheikha, H., Elmansy, L., Kalinich, C. C., Grubaugh, N. D., Shapiro, E. D., Initiative, Y. S.-C.-2. G. S., Billig, K., Breban, M. I., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.0935 · Cited by 31

Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals

Lechmere, T., Snell, L. B., Graham, C., Seow, J., Shalim, Z. A., Charalampous, T., Alcolea-Medina, A., Batra, R., Nebbia, G., Edgeworth, J. D., et al. (2022) · mBio · doi:10.1128/mbio.03798-21 · Cited by 30

Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021

Braeye, T., Catteau, L., Brondeel, R., van Loenhout, J. A. F., Proesmans, K., Cornelissen, L., Oyen, H. J. V., Stouten, V., Hubin, P., Billuart, M., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.025 · Cited by 33

COVID-19 Vaccination in Patients With Malignancy; A Systematic Review and Meta-Analysis of the Efficacy and Safety

Javadinia, S., Alizadeh, K., Mojadadi, M., Nikbakht, F., Dashti, F., Joudi, M., Harati, H., Welsh, J., Farahmand, S. A., & Attarian, F. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.860238 · Cited by 34

Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months

Sobieszczyk, M. E., Maaske, J., Falsey, A. R., Sproule, S., Robb, M. L., Frenck, R. W., Tieu, H., Mayer, K. H., Corey, L., Neuzil, K. M., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci160565 · Cited by 33

Breast cancer risk factors in Iranian women: a systematic review and meta-analysis of matched case–control studies

Khoramdad, M., Solaymani–Dodaran, M., Kabir, A., Ghahremanzadeh, N., Hashemi, E.-O.-S., Fahimfar, N., Omidi, Z., Mansournia, M. A., Olfatbakh, A., Salehiniya, H., et al. (2022) · European journal of medical research · doi:10.1186/s40001-022-00952-0 · Cited by 37

Six-Month Effectiveness of BNT162B2 mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort StudyPreprint

Tartof, S. Y., Slezak, J. M., Fischer, H. J., Hong, V. X., Ackerson, B. K., Ranasinghe, O. N., Frankland, T. B., Ogun, O. A., Zamparo, J. M., Gray, S., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3909743 · Cited by 30

Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant

Risk, M., Shen, C., Hayek, S. S., Holevinski, L., Schiopu, E., Freed, G. L., Akin, C., & Zhao, L. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac106 · Cited by 28

BNT162b2 (Pfizer–Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design

Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V. X., Xie, F., Ackerson, B. K., Valluri, S. R., Jódar, L., & McLaughlin, J. M. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00101-1 · Cited by 151

BNT162b2 Effectiveness and Durability Against BA.1 and BA.2 Hospital and Emergency Department Admissions in a Large US Health System: A Test-Negative DesignPreprint

Tartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V. X., Xie, F., Ackerson, B. K., Valluri, S. R., Jódar, L., & McLaughlin, J. M. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4150500 · Cited by 2

Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study

Fabiani, M., Puopolo, M., Morciano, C., Spuri, M., Alegiani, S. S., Filia, A., D’Ancona, F. “., Manso, M. D., Riccardo, F., Tallon, M., et al. (2022) · BMJ · doi:10.1136/bmj-2021-069052 · Cited by 111